NICODERM CQ (nda020165)- (7MG/24HR,14MG/24HR,21MG/24HR)

Generic Name	NICOTINE	Innovator	CHATTEM SANOFI
Dosage	7MG/24HR,14MG/24HR,21MG/24HR
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2021-May-22	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	NICODERM CQ is indicated to reduce the withdrawal symptoms, including nicotine craving, associated with quitting smoking.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
1	0	1

Other Developers

Total Other Developers	1

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
7MG/24HR	**	**	-	-	1
14MG/24HR	**	**	-	1	-
21MG/24HR	**	**	-	-	1

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	1

Manufacturing Details of NICODERM CQ